NASDAQ:CYAD Celyad Oncology (CYAD) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.40▼$0.6550-Day Range$0.59▼$0.8552-Week Range$0.46▼$3.07Volume3,009 shsAverage VolumeN/AMarket Capitalization$15.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Celyad Oncology alerts: Email Address Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Celyad Oncology Stock (NASDAQ:CYAD)Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Read More Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report CYAD Stock News HeadlinesJuly 19, 2024 | finance.yahoo.comCelyad Oncology SA (CYADB.XC)April 4, 2024 | finance.yahoo.comCelyad Oncology Reports Full Year 2023 Financial Results and Recent Business HighlightsJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! March 29, 2024 | seekingalpha.comCSBR Champions Oncology, Inc.January 17, 2024 | finanznachrichten.deCelyad Oncology SA: Celyad Oncology provides fourth quarter 2023 business update and 2024 outlookJanuary 16, 2024 | finance.yahoo.comCelyad Oncology provides fourth quarter 2023 business update and 2024 outlookDecember 17, 2023 | businesswire.comCelyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)December 4, 2023 | finance.yahoo.comCelyad Announces Management ChangeJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! November 14, 2023 | tmcnet.comInformation on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 MayNovember 11, 2023 | lse.co.ukCelyad Oncology Share Price (CYAD.BR)November 9, 2023 | finanznachrichten.deCelyad Oncology SA: Celyad Oncology reports third quarter 2023 financial results and recent business highlightsNovember 9, 2023 | finance.yahoo.comCelyad Oncology reports third quarter 2023 financial results and recent business highlightsSeptember 26, 2023 | finanznachrichten.deCelyad Oncology SA: Celyad Oncology announces the termination of its American Depository Receipt programSeptember 25, 2023 | marketwatch.comCelyad Oncology to Terminate ADR ProgramSeptember 25, 2023 | finance.yahoo.comCelyad Oncology announces the termination of its American Depository Receipt programSeptember 15, 2023 | finance.yahoo.comCelyad Oncology SA: Publication of a Rectified Transparency Notification Received From Fortress Investment Group LLCSeptember 12, 2023 | businesswire.comCelyad Oncology SA: Publication of a Transparency Notification Received from Tolefi SASee More Headlines Receive CYAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celyad Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYAD CUSIPN/A CIK1637890 Webwww.celyad.com Phone(210) 039-4100Fax321-039-4141Employees95Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.14 Current Ratio3.79 Quick Ratio3.79 Sales & Book Value Annual Sales$110,000.00 Price / Sales144.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book2.31Miscellaneous Outstanding Shares26,520,000Free Float26,276,000Market Cap$15.91 million OptionableNot Optionable BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesGeorges RawadiChief Executive Officer & Executive DirectorDavid GeorgesVice President-Finance & AdministrationEytan BremanDirector-Research & DevelopmentAn PhanHead-LegalKey CompetitorsAnebulo PharmaceuticalsNASDAQ:ANEBHookipa PharmaNASDAQ:HOOKProPhase LabsNASDAQ:PRPHAileron TherapeuticsNASDAQ:ALRNRockwell MedicalNASDAQ:RMTIView All Competitors CYAD Stock Analysis - Frequently Asked Questions When did Celyad Oncology IPO? Celyad Oncology (CYAD) raised $99 million in an IPO on Friday, June 19th 2015. The company issued 1,400,000 shares at a price of $70.98 per share. UBS Investment Bank and Piper Jaffray served as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers. What other stocks do shareholders of Celyad Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celyad Oncology investors own include Galapagos (GLPG), Cellectis (CLLS), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), ChromaDex (CDXC), bluebird bio (BLUE) and SCYNEXIS (SCYX). This page (NASDAQ:CYAD) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celyad Oncology SA Please log in to your account or sign up in order to add this asset to your watchlist. Share Celyad Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.